Rocket Lab's Neutron Slips and Wall Street Trims Its Ambitions
Published on 10/10/2026 at 09:30 | Editorial boerse-global.de
The romance has drained out of the space trade. Where a single clean engine burn once sent shares vertical, investors now want cadence, cash discipline and a valuation they can defend on a spreadsheet. Rocket Lab sits squarely in that uncomfortable gap between pioneering story and commercial proving ground — and the past week has made the tension impossible to ignore.
The stock finished Friday at EUR 60.90, roughly 54% below its 52-week high and down 7.3% over seven days. That slide is not noise. It reflects a set of hard operational hurdles management must clear in the coming quarters, and the market is no longer willing to pay in advance for success it cannot yet see.
Neutron's First Flight Drifts Further Out
The centerpiece of the bull case remains Neutron, the medium-lift vehicle meant to move Rocket Lab out of the small-payload niche and into the more lucrative weight class where SpaceX's Falcon 9 currently rules. That front is where the warnings are multiplying.
After cracks in the first stage forced a redesign of the fuel tank, chief executive Peter Beck acknowledged that a maiden launch before year-end is looking increasingly unlikely. The company still aims to deliver the rocket to the pad in the fourth quarter of 2026, but delays in space programs carry a heavy price. Every lost month adds financial strain, and the second-quarter 2026 free cash flow of minus USD 110.12 million makes the scale of that burden plain.
Guidance for the third quarter points to revenue of USD 250 million to USD 265 million, paired with an expected adjusted EBITDA loss of between USD 17 million and USD 23 million. Staying in this industry demands deep pockets.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Two Banks, Two Verdicts
Wall Street is already adjusting. Barclays initiated coverage on Thursday with an Overweight rating and an USD 85 price target. A day later, TD Cowen's Gautam Khanna kept his buy recommendation but slashed his target sharply from USD 120 to USD 90. Neither call abandons the long-term thesis, yet both mark a visible retreat from earlier highs.
The read-through is straightforward: the growth story is not being questioned outright, but the previous valuation had simply run too far ahead of the evidence.
A Multibillion-Dollar Bet on Iridium
Adding to the risk profile is Rocket Lab's agreement to acquire Iridium for roughly USD 8 billion. Some USD 1.94 billion has already been raised through share sales to fund the deal, which is not expected to close until mid-2027 and remains subject to regulatory approval. A transaction of that size absorbs enormous management attention at precisely the moment the core launch business should be the sole priority.
Electron Keeps Delivering
Against that backdrop, the legacy business continues to provide steady ballast. Synspective has contracted 20 additional Electron launches spanning 2028 to 2031, bringing the total between the two partners to 47 missions. The financial terms were not disclosed. For a launch provider, such multi-year bookings mean one thing above all: predictable capacity utilization for years ahead.
Rocket Lab is also working to defend its niche through technical flexibility. On August 10 it unveiled GHOST, a containerized, globally deployable launch system for Electron and HASTE missions. The first suborbital flight of that mobile setup is targeted for 2027 from Alaska.
An Insider Sale Lands Awkwardly
One development from roughly a week ago still lingers in the conversation. Chief financial officer Adam Spice sold 140,157 shares at an average price of USD 70.82, generating proceeds of USD 9,925,918.74. Such transactions run through pre-arranged Rule 10b5-1 trading plans, yet seven-figure cash-outs by senior management reliably leave a sour taste during volatile stretches.
The Tab the Market Is Already Footing
With a market capitalization equivalent to EUR 35.94 billion, the exchange is clearly pricing in substantial future success despite the recent target cuts. That is the crux of Rocket Lab's dilemma: the company must convert its technological edge into durable margins faster than the market's patience erodes. Until Neutron flies and operating losses shrink meaningfully, the shares are likely to stay vulnerable to setbacks — even with the long-term vision intact.
Ad
Rocket Lab Stock: New Analysis - 10 October
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
